This company listing is no longer active
NuGenerex Immuno-Oncology Dividends and Buybacks
Dividend criteria checks 0/6
Key information
n/a
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
No updates
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if NUGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NUGX's dividend payments have been increasing.
Dividend Yield vs Market
| NuGenerex Immuno-Oncology Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NUGX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (NUGX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate NUGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NUGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NUGX has not reported any payouts.